8-K
filed November 17, 2023, 6:59 PM ET
ticker INBS
CIK 0001725430
other material
confidence high
sentiment negative
materiality 0.75
INTELLIGENT BIO SOLUTIONS INC. (INBS): Nasdaq/NYSE listing notice — Intelligent Bio Solutions receives Nasdaq delisting notices for low equity and bid price
INTELLIGENT BIO SOLUTIONS INC.
- Received Nasdaq deficiency letter for stockholders' equity of $1.24M, below $2.5M minimum; must submit plan by Jan 2, 2024.
- Also received bid price deficiency; closing bid below $1.00 for 30 consecutive days; cure period until May 14, 2024.
- At special meeting, stockholders approved issuance of up to 15,921,888 shares upon exercise of warrants from Oct 2023 offering.
- Ratified UHY LLP as independent auditor for fiscal year ending June 30, 2024.
- Company believes it now meets equity requirement but no assurance of acceptance of compliance plan.
Key facts
Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.99
INTELLIGENT BIO SOLUTIONS INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).
- Exchange
- nasdaq
- Notice
- noncompliance notice
- Deficiency
- stockholders equity
- Rules
- 5550(b)(1)
Exact text from the filing
companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. In the Company’s Form 10-Q, the Company reported stockholders’ equity of $1,236,558, which is below the minimum stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). As indicated in Nasdaq’s letter, as of November 15,
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
INTELLIGENT BIO SOLUTIONS INC. shareholders approved Authorization of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1 at the 2023-11-17 meeting.
- Outcome
- passed
- Meeting
- 2023-11-17
Exact text from the filing
Proposal 3. Authorization of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1. VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 794,254 284,744 1,592 42,853
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
INTELLIGENT BIO SOLUTIONS INC. shareholders approved Ratification of the appointment of UHY LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024 at the 2023-11-17 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-11-17
Exact text from the filing
Proposal 2. R atification of the appointment of UHY LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024. VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 957,940 157,789 7,714 -0-
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
INTELLIGENT BIO SOLUTIONS INC. shareholders approved Approval, for purposes of complying with Nasdaq Listing Rules 5635(c) and (d), of the issuance of up to 15,921,888 shares of common stock (or 16,727,272 shares if the full overallotment option is exercised) upon the exercise of the Warrants issued by the Company in a public offering that closed on O at the 2023-11-17 meeting.
- Outcome
- passed
- Meeting
- 2023-11-17
Exact text from the filing
Proposal 1. A pproval, for purposes of complying with Nasdaq Listing Rules 5635(c) and (d), of the issuance of up to 15,921,888 shares of common stock (or 16,727,272 shares if the full overallotment option is exercised) upon the exercise of the Warrants issued by the Company in a public offering that closed on October 4, 2023 (“Proposal 1”). VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 509,897 116,224 2,040 495,282
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.